MoonLake Immunotherapeutics (MLTX) Share-based Compensation (2021 - 2026)
MoonLake Immunotherapeutics' (MLTX) quarterly Share-based Compensation came in at $13.4 million in Q1 2026, up 378.64% quarter-over-quarter from -$4.8 million in Q4 2024.
MoonLake Immunotherapeutics (MLTX) Share-based Compensation (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $13.4 million for Q1 2026.
- On a quarterly basis, Share-based Compensation changed N/A year-over-year to $13.4 million in Q1 2026; TTM through Mar 2026 was $13.4 million, a 1290.29% increase from a year earlier, with the FY2024 full-year figure at $555000.0, down 92.19% from the prior year.
- Share-based Compensation rose to $13.4 million in Q1 2026 per MLTX's latest filing, from -$4.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $13.4 million in Q1 2026 and bottomed at -$4.8 million in Q4 2024.
- The 4-year median for Share-based Compensation is $2.0 million (2022), against an average of $2.4 million.
- Biggest YoY gain for Share-based Compensation was 249.17% in 2024; the steepest drop was 398.54% in 2024.
- Year by year, Share-based Compensation stood at $2.6 million in 2022, then sank by 38.17% to $1.6 million in 2023, then tumbled by 398.54% to -$4.8 million in 2024, then surged by 378.64% to $13.4 million in 2026.
- Per Business Quant, the three latest MLTX Share-based Compensation figures stand at $13.4 million (Q1 2026), -$4.8 million (Q4 2024), and $5.0 million (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | MoonLake Immunotherapeutics | 1.35 Bn | 991.29 Mn | - | 13.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.36 Mn |
| Mar 31, 2026 | 13.36 Mn |
| Dec 31, 2024 | -4.79 Mn |
| Dec 31, 2024 | -4.79 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Jun 30, 2024 | -1.31 Mn |
| Jun 30, 2024 | -1.31 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 2.58 Mn |
| Mar 31, 2023 | 2.58 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Dec 31, 2022 | 2.60 Mn |